Wegovy pill widens UAE obesity care

UAE patients are set to gain early access to Novo Nordisk’s Wegovy pill through Metabolic, marking a significant shift in obesity treatment as the once-daily oral semaglutide formulation enters the country’s fast-evolving metabolic health market.

The move follows regulatory approval by the Emirates Drug Establishment for Wegovy as an oral treatment for long-term weight management in adults living with obesity or those overweight with at least one weight-related medical condition. The UAE has become the second country globally to authorise the treatment, placing it among the earliest markets to adopt the pill after its US approval.

Metabolic, formerly GluCare. Health, is positioning the medicine within a physician-led metabolic health programme rather than as a stand-alone slimming product. That model reflects a broader shift in obesity care, where GLP-1 therapies are increasingly being prescribed alongside nutrition support, physical activity, behavioural counselling and monitoring of cardiometabolic risk.

Wegovy pill contains semaglutide 25 mg, the same active molecule behind Novo Nordisk’s injectable Wegovy and Ozempic, but is formulated as a daily tablet. The product belongs to the glucagon-like peptide-1 receptor agonist class, which works by regulating appetite, slowing gastric emptying and improving metabolic signals linked to hunger and satiety. For patients reluctant to use injections, the tablet format could remove one of the barriers to starting treatment, although daily dosing and administration requirements will remain important factors in adherence.

Clinical results supporting the approval showed substantial weight reduction in adults with obesity or overweight and related conditions. A late-stage trial of oral semaglutide 25 mg recorded mean body-weight loss of 16.6 per cent over 64 weeks among patients who adhered to treatment, compared with 2.7 per cent for placebo. One in three participants achieved weight loss of 20 per cent or more. The safety and tolerability profile was described as consistent with established semaglutide data, with gastrointestinal effects such as nausea, vomiting, diarrhoea and constipation among the commonly observed reactions in the GLP-1 class.

The UAE approval also covers reduction of major adverse cardiovascular events in high-risk patients, including cardiovascular death, heart attack and stroke, when used in line with approved indications. That aspect is central to the therapy’s public-health relevance, as obesity is closely associated with type 2 diabetes, hypertension, dyslipidaemia, fatty liver disease, sleep apnoea and cardiovascular complications.

Demand is likely to be strong. The UAE’s latest national health data showed 22.4 per cent of adults living with obesity, while 25.9 per cent had high blood pressure, 12.5 per cent had elevated blood glucose and 54.2 per cent had high cholesterol. These figures underline the pressure on healthcare providers to move beyond episodic weight-loss interventions towards sustained disease management.

The launch also comes as the global obesity-drug market becomes one of the most competitive areas in pharmaceuticals. Novo Nordisk and Eli Lilly are racing to expand injectable and oral GLP-1 portfolios as analysts expect the category to exceed $100 billion in annual sales over the next decade. Oral formulations are viewed as a key route to broader adoption because they may suit primary-care settings, patients with injection hesitancy and health systems seeking easier dispensing models.

Novo Nordisk gained first-mover advantage in the oral GLP-1 weight-management segment after the US approval of Wegovy pill in December 2025, followed by a US launch in January 2026. European regulators have also recommended approval, with a final decision expected from the European Commission. Those milestones have increased the strategic importance of early-access markets such as the UAE, where health authorities have sought faster evaluation pathways for advanced therapies while maintaining regulatory oversight.

Metabolic’s role in the UAE rollout may be watched closely by hospitals, insurers and digital-health operators. Its hybrid care model combines clinical supervision with continuous data tracking, an approach that may become more relevant as obesity drugs move from specialist clinics to broader chronic-care pathways. The model also raises questions over pricing, reimbursement, patient selection and long-term follow-up, particularly because GLP-1 therapies often require sustained use to maintain benefits.

Doctors are expected to screen patients carefully before prescribing the pill. Wegovy is not intended for cosmetic weight loss and is indicated for adults meeting obesity or overweight criteria with associated medical risks. Patients with certain endocrine conditions, a history of specific thyroid cancers or other contraindications require medical assessment. Treatment should also be paired with reduced-calorie nutrition, increased physical activity and monitoring for side effects.

The oral formulation may improve convenience, but it is not free from practical constraints. Semaglutide tablets must typically be taken under specific fasting conditions to support absorption, and patients may need counselling to avoid missed doses or incorrect administration. That requirement could influence real-world outcomes, especially among patients managing multiple medicines.